New COVID-19 drug candidate passes first safety check in healthy volunteers
NCT ID NCT05532293
First seen Feb 03, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This early-stage study tested a new oral drug called MSP008-22 in 64 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects. This study does not test whether the drug treats or prevents COVID-19, but gathers essential safety data for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ashirwad Hospital & Research Centre, Maratha Section, Near Jijamata Udyan, Ulhasnagar, Maharashtra, India
Ulhasnagar, Maharashtra, 421004, India
-
K. J. Somaiya Hospital & Research Centre, Somaiya Ayurvihar Complex, Eastern Express Highway, Sion East
Mumbai, Maharashtra, 400022, India
Conditions
Explore the condition pages connected to this study.